Inline-six engines are the beating heart of a certain German automaker - here's the most powerful of them all.

CSL management originally forecast revenue growth of 4-5% and net profit after tax before amortisation (NPATA) growth of 7-10 ...

When we bought the E46 M3 CSL, we said it was perfect just the way it was, but resisting modifications was never going to ...

With plasma collection as its stock-in-trade, the struggles of CSL during the coronavirus lockdown were understandable. But a rebound—fueled by a surge in post-pandemic collections and an $11.7 ...

CSL shares have fallen almost 40% in 2025. Investors are now asking if the worst is already behind the stock. The post Will ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Of all the performance suffixes you can attach to a BMW, CSL (short for Competition Sport Lightweight) may just be the one that creates the highest of expectations. Hopefully, BMW has brought its ...

We had reports that a beastly new CSL edition of the BMW M4 would arrive this May. It’s now May, and BMW has just unleashed a new M4 CSL, a car that — at least on paper — may lay claim to the crown as ...

Steven Ewing spent his childhood reading car magazines, making his career as an automotive journalist an absolute dream job. After getting his foot in the door at Automobile while he was still a ...

After an antitrust review knocked 2021’s biggest biopharma buyout off course in May, CSL’s $11.7 billion deal for Swiss iron deficiency specialist Vifor Pharma appears to be back on track. Tuesday, ...

CSL Limited, a biotechnology company that produce many of its biological products from plasma, is diversifying its portfolio and its drug pipeline through its largest ever acquisition: the purchase of ...

CSL Behring’s largest-ever trial has ended in failure, as the Australian pharma revealed that its cholesterol efflux enhancer was unable to reduce the risk of heart attacks. The company had been ...